Centene Corp. CNC

NYSE · Healthcare · Medical - Healthcare Plans

$63.78

Close on Fri, 20 Nov 2026 · market value $31.6B

What the price is betting on

Below its record

At $64, the price assumes revenue shrinks about 34% a year for five years, from $204B to about $35.1B by FY2030. That is about the same as what analysts expect for the next two years and less than the company's own last three years.

The price assumes−34%
Analysts, next two years−1.3%
Last 3 years11%

Revenue growth a year. The price figure comes from a reverse DCF at a 9.3% discount rate.

Track it and Parra checks each report against the path, and tells you when revenue falls behind it.

Own more than CNC? Check up to 5 of your stocks at once, free, no account.

0$100B$200B$300B$204B'22'23'24'25Sep '26'26'27'28'29'30What the price needsReportedAnalysts

Both sides

Three stories, three values

Bear

$147

Base

$158

Bull

$172

Today $64

  • Bear $147. Cash flow grows -1% a year for the next 5 years, slower than expected, then slows to long-run growth.
  • Base $158. Cash flow grows 1% a year for the next 5 years, as analysts expect, then slows to long-run growth.
  • Bull $172. Cash flow grows 3% a year for the next 5 years, faster than expected, then slows to long-run growth.

Stories set by rules from the company’s record.

Checkpoints

The revenue the price needs

  1. YearNeedsAnalysts expect
  2. FY2026$184B$200B, on the path
  3. FY2027$122B$196B, on the path
  4. FY2028$80.3B$200B, on the path
  5. FY2029$53.1B$211B, on the path
  6. FY2030$35.1B$213B, on the path

Each year's revenue at −34% growth from $204B in the 12 months to September 2026.

At a glance

Healthcare · Medical - Healthcare Plans · listed on NYSE

Revenue, FY2025
$195B
Growth, 3 years a year
11%
Cash margin
2.2%
Net cash
$2.2B
Shares, 3-year change
−16%
Dividend yield
0%

What other healthcare prices are betting on

Figures from company filings and end-of-day market data, as of the close on Fri, 20 Nov 2026; updated every trading day. This page shows what today's price assumes, not whether to buy or sell. Not investment advice.